First report of hop stunt viroid infecting luffa and cantaloupe in Taiwan.

Luffa (Luffa cylindrica (L.) M. Roem.

Bacterial Outer Membrane Vesicle (OMV)-Encapsulated TiO Nanoparticles: A Dual-Action Strategy for Enhanced Radiotherapy and Immunomodulation in Oral Cancer Treatment.

Oral squamous-cell carcinoma (OSCC) poses significant treatment challenges due to its high recurrence rates and the limitations of current therapies. Titanium dioxide (TiO) nanoparticles are promising radiosensitizers, while bacterial outer membrane vesicles (OMVs) are known for their immunomodulatory properties. This study investigates the potential of OMV-encapsulated TiO nanoparticles (TiO@OMV) to combine these effects for improved OSCC treatment.

An integrated microflow cytometry platform with artificial intelligence capabilities for point-of-care cellular phenotype analysis.

The EZ DEVICE is an integrated fluorescence microflow cytometer designed for automated cell phenotyping and enumeration using artificial intelligence (AI). The platform consists of a laser diode, optical filter, objective lens, CMOS image sensor, and microfluidic chip, enabling automated sample pretreatment, labeling, and detection within a single compact unit. AI algorithms segment and identify objects in images captured by the CMOS sensor at 532 and 586 nm emission wavelengths.

Cross-facility absolute charge calibration of scintillating screens for laser wakefield accelerated beam diagnostics.

Scintillation screens are widely used to diagnose high-charge density, low-average current electron beams from laser wakefield accelerators (LWFAs). However, the absolute response between emitted photons and electron charge has only been calibrated at a limited number of facilities, and there have been discrepancies between these calibrations. In this report, we comprehensively revised the absolute charge calibration of two high relative brightness scintillating screens of LANEX Regular (Carestream) and PI200 (Mitsubishi) by employing the high-brightness photoinjector at the National Synchrotron Radiation Research Center (NSRRC), which provides electron beams with variable charges (50-350 pC per pulse) and energies (26.

Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.

Background: Immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE). Glucagon-like peptide-1 agonists (GLP1a), initially developed for type 2 diabetes mellitus (T2DM), have shown promising results in reducing cardiovascular events. We aimed to investigate the effect of GLP1a on cardiovascular events in patients receiving ICIs.